Paxman AB (publ) (STO:PAX)
Sweden · Delayed Price · Currency is SEK | Market Cap | 1.14B -12.0% |
| Revenue (ttm) | 323.56M +22.9% |
| Net Income | -16.72M |
| EPS | -0.72 |
| Shares Out | 23.27M |
| PE Ratio | n/a |
| Forward PE | 25.65 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,204 |
| Average Volume | 18,663 |
| Open | 48.05 |
| Previous Close | 49.00 |
| Day's Range | 47.65 - 49.70 |
| 52-Week Range | 41.00 - 85.80 |
| Beta | 0.44 |
| RSI | 51.91 |
| Earnings Date | May 22, 2026 |
About Paxman AB
Paxman AB (publ), together with its subsidiaries, develops and sells Paxman scalp cooling system to minimize hair loss in connection with chemotherapy treatment worldwide. It serves various cancer centers and hospitals. The company has collaborated with the University of Huddersfield and the University of Leeds to develop a wearable medical cooling device; and the National University Hospital of Singapore for the development of a cooling and compression system. Paxman AB (publ) was founded in 1996 and is headquartered in Karlshamn, Sweden. [Read more]
Financial Performance
Financial StatementsNews
Paxman AB Transcript: DNB Carnegie Healthcare Seminar 2026
Significant growth in 2025 was driven by a major acquisition, record sales, and a strategic shift to insurance-based billing in the US. Regulatory progress and new product launches are set to accelerate growth, with a focus on operational excellence and expanding standard of care globally.
Paxman AB Earnings Call Transcript: Q4 2025
Q4 saw strong sales growth driven by the Dignitana acquisition and robust U.S. insurance-based billing, with group net sales up to SEK 84 million. Strategic focus is on U.S. expansion, new product launches, and leveraging CPT I codes for improved reimbursement.
Paxman AB Transcript: DNB Carnegie Småbolagsdag
The company is rapidly expanding in medtech, focusing on cryotherapy for chemotherapy side effects and transitioning to an insurance-based billing model to drive U.S. growth. Key priorities include integrating a major competitor, launching new products, and leveraging legislative changes for broader insurance coverage by 2026.
Paxman AB Transcript: CMD 2025
Key strategic priorities include accelerating the insurance-based billing model, launching new alopecia and neuropathy products, and expanding U.S. and select international markets. Strong clinical data and regulatory progress support commercialization, while the Dignitana integration enhances scale and profitability. Focus remains on operational excellence, patient impact, and sustainable growth.
Paxman AB Earnings Call Transcript: Q3 2025
Record Q3 revenue driven by Dignitana integration and strong US focus, with EBITDA margin at 9%. CIPN commercialization and insurance-based billing remain key growth drivers, while legislative and regulatory developments support future expansion.
Paxman AB Earnings Call Transcript: Q2 2025
Sales grew 17% year-over-year, driven by the Dignitana acquisition and strong international demand. Integration and restructuring are on track, with cost synergies and improved margins expected by year-end. Cash reserves remain robust at over SEK 149 million.
Paxman AB Earnings Call Transcript: Q1 2025
Achieved record Q1 sales with 14.5% growth and strong U.S. performance, but reported a forex-driven net loss. Completed the Dignitana merger, raised SEK 120 million, and advanced U.S. reimbursement and CIPN commercialization initiatives.